金山科研平台，产品价格货期咨询微信：jinshanbio Source:E. coli-derived, Ser2-Glu455, with an N-terminal Met and 6-His tag Accession #:Q13867 N-terminal Sequence Analysis:Met Purity:>90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 µg per lane. Endotoxin Level: Predicted Molecular Mass:53 kDa SDS-PAGE:45-50 kDa, reducing conditions Activity:Measured by its ability to hydrolyze Met-AMC.The specific activity is >500 pmol/min/µg, as measured under the described conditions. Formulation:Supplied as a 0.2 µm filtered solution in Tris, NaCl, Glycerol and DTT.See Certificate of Analysis for details. Molecule Information: BLMH/Bleomycin Hydrolase Aliases: BMH Entrez Gene IDs: 642 (Human) Background: BLMH Bleomycin hydrolase (BLMH) is a cysteine peptidase of the papain superfamily. It is named for its ability to hydrolyze the anti-tumor agent bleomycin and inactivate it. It has a papain-like catalytic triad (Cys-His-Asp) with optimum activity at neutral pH. In mammals it is expressed ubiquitously in all types of tissues and its expression is up-regulated in many tumors. It is present in the cytoplasm as homohexameric protein of approximately 300 kDa. In addition to its aminopeptidase activity, it has homocysteine-thiolactonase activity. The normal physiological function of BLMH is not clear. BLMH inactivates bleomycin, a glycopeptide anti-cancer agent, by deaminating it. BLMH has been suggested to play a role in the generation of MHC class I-presented peptides. Diminished BLMH activity may contribute to the pathology of Alzheimer's disease. It is inhibited by cysteine protease inhibitors such as N-ethylmaleimide, iodoacetamide, para-hydroxymercuribenzoate, and E-64.